ESR1 and breast cancer: Furthermore, among the common breast cancer subtypes, higher pCR rates were observed in ER-negative (ER−), luminal B HER2-negative (HER2−), nonluminal HER2+, and triple-negative (ER−, progesterone receptor [PgR]-negative, and HER2−) disease [16].